GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
GeneCentric Therapeutics has raised $8.0M in total funding. The most recent round was Series C. The last funding was announced in June 2025.
GeneCentric Therapeutics's investors include LabCorp, Dow Jones, Hatteras Venture Partners, Alexandria Venture Investments, IAG Capital Partners.
GeneCentric Therapeutics is headquartered in Durham, United States.
GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
GeneCentric Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GeneCentric Therapeutics — Funding & Investors." VCBacked, June 18, 2025, https://www.vcbacked.co/company/genecentric-therapeutics. Accessed September 14, 2026.
VCBacked. (2025). GeneCentric Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/genecentric-therapeutics
{{cite web |title=GeneCentric Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/genecentric-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated